Efficacy

Related by string. efficacy * * primary efficacy endpoint . secondary efficacy endpoints . Demonstrates Efficacy . efficacy endpoints . vivo efficacy . primary efficacy endpoints . efficacy tolerability . luminous efficacy . antimicrobial efficacy . antiviral efficacy . preclinical efficacy . therapeutic efficacy . efficacy endpoint . analgesic efficacy . secondary efficacy endpoint *

Related by context. All words. (Click for frequent words.) 73 Tolerability 67 Pharmacokinetic 66 efficacy 66 Clinical Efficacy 66 Monotherapy 66 Controlled Study 66 Long Term Efficacy 65 Controlled Trial 65 Antiviral Activity 65 Pharmacokinetics 65 Patients Treated 64 Randomized Double Blind Placebo 64 Safety Tolerability 63 Enoxaparin 63 Well Tolerated 63 Combination Therapy 63 Immunogenicity 62 Double Blind Placebo 62 Clinical Trial Results 62 Randomized Controlled Trial 62 Relapsing Multiple Sclerosis 62 Tiotropium 62 Randomised 62 Clopidogrel 62 Phase III Trial 62 Pharmacodynamics 62 analgesic efficacy 62 Study Evaluating 62 Pharmacokinetic Study 61 Placebo Controlled Trial 61 Antitumor Activity 61 II Clinical Trial 61 Platelet Inhibition 61 Randomized Clinical Trial 61 ritonavir boosted 61 Meta Analysis 61 Patency 61 Pooled Analysis 61 Pediatric Patients 61 Randomized 61 Statistically Significant 61 Epoetin Alfa 61 Treatment Naive HIV 60 Elderly Patients 60 Randomized Double Blind 60 Demonstrates Positive 60 Randomized Phase 60 Demonstrated Significant 60 Oral Fingolimod 60 Versus Placebo 60 Prospective Randomized 60 Orally Active 60 Plus Ribavirin 60 Meets Primary Endpoint 60 Non Inferiority 60 Pivotal Phase 60 Capecitabine 60 Chronic Hepatitis C 60 Anti Tumor Activity 60 Randomized Evaluation 59 Bivalirudin 59 Sustained Efficacy 59 Patients Receiving 59 Low Dose 59 Extended Release 59 Survival Benefit 59 Patients Treated With 59 Efficacy Study 59 Unfractionated Heparin 59 Phase III Clinical Trial 59 Insulin Glargine 59 Pharmacokinetics PK 59 Statin Therapy 59 Infected Patients 59 Dose Response 59 multicenter randomized 59 Peginterferon 59 icatibant 59 Relapsing Remitting Multiple Sclerosis 59 Infliximab 59 Peginterferon Alfa 2a 59 Phase IIb Trial 59 Dose Escalation 59 tolerability 59 Potent Antiviral Activity 59 pharmacokinetics PK 59 JAK Inhibitor 59 Free Survival PFS 59 Pioglitazone 59 Patients Undergoing 59 Adalimumab 58 Protease Inhibitor 58 Study Demonstrates 58 Percutaneous Tibial Nerve Stimulation 58 Study Showed 58 Investigational Compound 58 antiviral efficacy 58 Placebo Controlled Study 58 Treated Patients 58 colesevelam HCl 58 randomized multicenter 58 Anti Tumor 58 Adjuvant Therapy 58 Shows Efficacy 58 Nilotinib 58 viral kinetics 58 Acute Ischemic Stroke 58 Pharmacodynamic 58 nab paclitaxel 58 Kidney Function 58 Hypertensive Patients 58 Prospective Randomized Trial 58 Phase 2b Study 58 fosbretabulin 58 Bioavailability 58 Initiated Phase 58 Pivotal Phase III 58 Subgroup Analysis 58 Phase IIb Clinical Trial 58 Previously Treated 58 Sirolimus Eluting Stent 58 PEG IFN 58 Demonstrates Potent 58 ziprasidone 58 Stent Restenosis 58 QD dosing 58 Phase 2b Clinical Trial 58 Randomized Placebo Controlled Trial 58 Treating Chronic 58 Disease Progression 58 Capsules CII 58 Autologous Stem Cell Transplantation 58 Postmenopausal Women 58 Cyclophosphamide 58 Clinical Outcome 57 TLUS 57 Trial Evaluating 57 Treatment Naive 57 Appears Safe 57 Preclinical Data 57 EURIDIS 57 Prolongs Survival 57 unfractionated heparin UFH 57 multicentre randomized 57 Vildagliptin 57 Hemodialysis Patients 57 Double Blind Randomized 57 multicenter multinational 57 Clinical Study 57 Demonstrates Significant 57 TAXUS ATLAS 57 Antitumor 57 Fulvestrant 57 Reduced Incidence 57 Venous Thromboembolism 57 Virologic 57 TRANSFORMS 57 Multicenter 57 Randomized Study 57 Pivotal Trial 57 Eluting 57 Desvenlafaxine Succinate 57 placebo controlled 57 Pivotal Study 57 Preclinical Study 57 Solid Tumors 57 Pegylated Liposomal Doxorubicin 57 Clinical Trial Evaluating 57 Completes Enrollment 57 #mg BID [003] 57 Heart Failure Patients 57 Randomized Double blind 57 administered subcutaneously 57 Tolvaptan 57 Gemcitabine 57 Improves Survival 57 Fixed Dose 57 Systematic Review 57 Zoledronic Acid 57 Abciximab 57 tiotropium 57 Myocardial Infarction Study 57 Demonstrates Efficacy 57 insulin detemir 57 Septic Shock 56 Loading Dose 56 alpha 2a 56 Glatiramer Acetate 56 efavirenz EFV 56 Efficacious 56 pharmacodynamic 56 Eluting Stent 56 Efficacy Results 56 Viral Suppression 56 Anticancer Activity 56 Neoadjuvant 56 Placebo controlled 56 lopinavir r 56 Phase III Pivotal Trial 56 HCV SPRINT 56 efficacy tolerability 56 Newly Diagnosed Multiple Myeloma 56 Decitabine 56 Ziprasidone 56 Glycemic Control 56 phase IIIb 56 Teriflunomide 56 Drug Candidate 56 Aliskiren 56 Linagliptin 56 Dose Ranging Study 56 Cardiovascular Events 56 Acute Myocardial Infarction 56 Naive Patients 56 Traficet EN 56 Pharmacokinetic PK 56 subcutaneously administered 56 Tocilizumab 56 Bare Metal Stents 56 Efficacy Trial 56 Presents Preclinical Data 56 Risedronate 56 Adjuvant Treatment 56 5 Fluorouracil 56 Phase 2a Clinical Trial 56 melphalan prednisone 56 Intravitreal 56 alfa 2a 56 Treatment Resistant 56 Renal Cell Carcinoma 56 PEGylated interferon beta 1a 56 Randomized Phase II 56 Antihypertensive 56 Stent Implantation 56 Chemotherapeutic Agents 56 Single Dose 56 teriflunomide 56 phase Ib 56 pharmacodynamic PD 56 Treatment Naive Patients 56 DASISION 56 Hormone Refractory Prostate Cancer 56 randomized multicenter trial 56 Presents Positive 56 Ranolazine 56 pharmacokinetic PK 56 Denufosol 56 Is Well Tolerated 56 limiting toxicity DLT 56 RE LY ® 56 RE SURGE 56 Disease Severity 56 Extended Release Formulation 56 Bortezomib 56 Adefovir 56 Prospective Multicenter 56 Improves Outcomes 56 noninferiority 56 peginterferon alfa 2b 56 adalimumab 56 bosentan 56 Completes Patient Enrollment 56 CIMZIA TM 56 Antiviral Therapy 56 Antipsychotic 56 Molecular Weight Heparin 56 Demonstrate Significant 56 non inferiority 56 tolerability profiles 56 FOLPI 56 Relapsed 56 Anti TNF 55 Tolerability Study 55 Valsartan 55 Diabetic Patients 55 Restenosis 55 multicenter randomized double 55 Melphalan 55 Relapsed Multiple Myeloma 55 Cypher Sirolimus 55 Immunosuppression 55 Primary Endpoint 55 Phase IIa Clinical Trial 55 Peginterferon Alfa 2b 55 Endpoints 55 plasma pharmacokinetics 55 Prophylaxis 55 Randomized Controlled 55 dose regimens 55 active comparator 55 Metastatic Melanoma 55 prospective randomized placebo 55 mg QD 55 Therapeutic Efficacy 55 Shows Statistically Significant 55 Vivo Efficacy 55 Adjuvant 55 Cost Effectiveness 55 Clinical Outcomes 55 ROCKET AF 55 Cethromycin 55 zonisamide SR 55 Eculizumab 55 Investigational Drug 55 Left Ventricular Dysfunction 55 Percutaneous Coronary Intervention 55 pharmacodynamics PD 55 Metabolic Efficiency 55 RE LY 55 calcipotriene 55 Rosuvastatin 55 Cardiovascular Outcomes 55 tolerability profile 55 randomized placebo controlled 55 Rheumatoid Arthritis Patients 55 Phase IIIb 55 Glucose Control 55 KRN# 55 rapid virologic response 55 Protease Inhibitors 55 liposome injection 55 Rivaroxaban 55 daily Infergen 55 Randomized Controlled Trials 55 Overactive Bladder 55 Pivotal Trials 55 Rating Scale MADRS 55 Successfully Completes Phase 55 multicenter randomized placebo controlled 55 GOUT 55 Endovascular Valve Edge 55 Hsp# Inhibitor 55 Darbepoetin Alfa 55 Relapsed Refractory 55 Initiate Phase 55 Refractory Hodgkin Lymphoma 55 Lanthanum Carbonate 55 pegylated interferon alfa 2b 55 Tipranavir 55 Sustained Virologic Response 55 Regimens 55 Novel Oral 55 nonrandomized 55 Multiple Ascending Dose 55 Lipid Levels 55 Golimumab 55 First Patient Dosed 55 Significantly Improves 55 Phase Ib II 55 mg BID 55 Combination Treatment 55 virologic response 55 Metastatic Renal Cell Carcinoma 55 SABCS 55 Carotid Stenting 55 Lacosamide 55 ISTODAX ® 55 randomized clinical 55 Telbivudine 55 Vitro Activity 55 Metastatic Prostate Cancer 55 multicenter prospective 55 candesartan cilexetil 54 Mycophenolate Mofetil 54 Adjuvant Chemotherapy 54 Sipuleucel T 54 SCH # 54 ExTRACT TIMI 54 Placebo Controlled 54 Postmarketing 54 Montgomery Asberg Depression 54 ACTEMRA TM 54 Androxal TM 54 Renal Function 54 Doxil ® 54 Risk Stratification 54 Demonstrates Sustained 54 Pegylated Interferon 54 Bosutinib 54 Celecoxib 54 Dapagliflozin 54 Natalizumab 54 Oritavancin 54 randomized controlled clinical trials 54 oral rivaroxaban 54 Ribavirin 54 Events MACE 54 Adjunctive Therapy 54 NEVO RES 54 prospective multicenter randomized 54 Tablet Formulation 54 Subcutaneous 54 Left Ventricular 54 Multicenter Study 54 Aflibercept 54 Medoxomil 54 prospective randomized 54 demonstrated statistically significant 54 Demonstrates Statistically Significant 54 pharmacokinetic PK study 54 Tumor Response 54 Primary endpoints 54 plus COPEGUS 54 Randomized Trials 54 Radiofrequency Ablation 54 Omacetaxine mepesuccinate 54 placebo controlled studies 54 Nucleoside 54 Randomized Comparison 54 Depressive Symptoms 54 EXPAREL ™ 54 Hematological Cancers 54 ascending dose 54 Suicidality 54 prucalopride 54 multicenter randomized controlled 54 relapsed MM 54 Nebulized 54 Universal Flu Vaccine 54 prospective randomized controlled 54 Paclitaxel Eluting 54 Significantly Reduces 54 Significantly Improved 54 lacosamide 54 Hepatic Encephalopathy 54 pharmacodynamic parameters 54 multicenter phase 54 APTIVUS 54 Fungal Infections 54 Improved Survival 54 Eszopiclone 54 coadministration 54 blind randomized placebo 54 Randomized Clinical Trials 54 satraplatin Phase 54 Attenuates 54 Metastatic Colorectal Cancer 54 TAXUS Liberte Long 54 Multicenter Phase 54 CYPHER R Sirolimus Eluting 54 Non Responders 54 mg kg BID 54 Bevacizumab 54 Pemetrexed 54 Multicenter Randomized Double 54 Non inferiority 54 EVEREST II 54 Myocardial Infarction 54 Lung Cancer Trial 54 Partial Onset Seizures 54 everolimus eluting stents 54 mg dose 54 Phase 2b Trial 54 Dose Escalation Study 54 Colorectal Cancer Patients 54 Investigational Agent 54 plus prednisone 54 Myocardial Ischemia 54 HDAC Inhibitor 54 Adenoma Prevention 54 achieved statistical significance 54 Bosentan 54 trials RCTs 54 ORENCIA ® 54 Secondary Endpoints 54 Unresectable 54 PERSEUS 54 BARACLUDE ® 54 Xeloda ® 54 Nasal Spray 54 Knee Osteoarthritis 54 mg TID 54 fosamprenavir 54 Advanced Prostate Cancer 54 INVEGA ® 54 Polymerase Inhibitor 54 tocilizumab 54 Localized Prostate Cancer 54 Blind Placebo Controlled Trial 54 Scale PANSS 54 Intracranial Aneurysms 54 salmeterol fluticasone 54 Moxifloxacin 54 Castration Resistant Prostate Cancer 54 Interferon Beta 54 Dosed 54 Radical Prostatectomy 54 Intervention Trial 54 PEGINTRON TM 54 Beneficial Effects 54 Lupus Drug 54 randomized 54 Bone Mineral Density 54 Long Lesion 54 Viral Load 54 Clinical Evaluation 54 Dual Antiplatelet Therapy 54 pharmacodynamic profiles 54 Renal Artery 54 Prophylactic Treatment 54 Inhibits 54 TO AVOID PREGNANCY WHILE 54 MabCampath 54 Tumor Progression 54 FOLFOX 54 Immune Responses 54 #mg QD [002] 54 C Reactive Protein 54 reactogenicity 53 double blind placebo 53 peginterferon alfa 2a #KD 53 Pegylated 53 Bioequivalence 53 Pegasys ® 53 Randomized Trial 53 Sirolimus Eluting 53 Significantly Reduced 53 Effectiveness 53 Hepatocellular Carcinoma 53 Antiplatelet Therapy 53 Drug Eluting 53 NDA Submission 53 preclinical efficacy 53 Randomized phase 53 RECIST Response Evaluation Criteria 53 CCX# B 53 Effectively Treats 53 ENDEAVOR II 53 Endarterectomy 53 TM Drug Eluting 53 Drug Eluting Stent 53 budesonide formoterol 53 Sandostatin R 53 Severe Sepsis 53 Initiates Phase 53 NSABP B 53 Edge STudy 53 Inhaled Corticosteroids 53 Treatment Regimen 53 dose proportionality 53 TMC# C# 53 Pulmonary Arterial Hypertension 53 secondary endpoints 53 Phase 2a Trial 53 Inhaled Liposomal Ciprofloxacin 53 Significant Improvement 53 Phase IIB 53 REYATAZ r 53 Previously Untreated 53 tacrolimus ointment 53 Lantus R 53 PRoFESS 53 AZILECT R 53 interferon gamma 1b 53 progression TTP 53 demonstrated clinically meaningful 53 Novel Compound 53 desvenlafaxine succinate 53 lanthanum carbonate 53 symptomatic paroxysmal AFib 53 HCV Genotype 53 Toxicities 53 atazanavir sulfate 53 NATRECOR ® 53 INCB# [003] 53 delafloxacin 53 nicardipine 53 posaconazole 53 Secondary endpoints 53 Small Molecule 53 Novel Inhibitor 53 ribavirin RBV 53 PEGASYS ® 53 Late Breaker 53 Phase III Trials 53 nebulized formoterol fumarate 53 boosted protease inhibitor 53 Advanced Melanoma 53 leukopenia pancytopenia thrombocytopenia 53 Thrombolysis 53 Helicobacter pylori eradication 53 Posaconazole 53 Multicenter Randomized 53 #mg/day [002] 53 double blinded randomized 53 Esomeprazole 53 Advanced Pancreatic Cancer 53 Anticoagulant 53 Sustained Release 53 abacavir lamivudine 53 8mg/kg 53 Blood Pressure Lowering 53 Inhalation Solution 53 Therapy Reduces 53 CIMZIA R 53 RE MODEL 53 prospective randomized multicenter 53 Atypical Antipsychotic 53 pegylated liposomal doxorubicin 53 Randomized controlled 53 amprenavir 53 Cognitive Function 53 Cardiac Function 53 mycophenolate mofetil 53 intravenous dosing 53 Treatment Outcome 53 Predictive Value 53 oxycodone CR 53 Confirms Efficacy 53 BAL# [002] 53 Kidney Transplant Patients 53 immunogenicity 53 Indacaterol 53 randomized double 53 Carotid Endarterectomy 53 randomized controlled clinical 53 serum phosphorus 53 Cytotoxicity 53 Patient Outcomes 53 sunitinib Sutent ® 53 Achieves Primary Endpoint 53 aripiprazole Abilify 53 Tracleer R 53 Initiates Clinical Trial 53 Daptomycin 53 standard chemotherapy regimen 53 Hypercholesterolemia 53 R# #mg BID 53 Renal Insufficiency 53 Non Invasive 53 Infarct 53 Statistical Significance 53 Intervention Effectiveness 53 quetiapine XR 53 PRTX 53 certolizumab 53 Bare Metal Stent 53 CALGB # [002] 53 Safinamide 53 Clinical Trial 53 viral kinetic 53 Severe Asthma 53 Negative Syndrome 53 Parathyroid Hormone 53 CANCIDAS 53 divalproex sodium 53 tolerability pharmacokinetics 53 pioglitazone 53 placebo controlled trials 53 TMC# r 53 Orthostatic Hypotension 53 PREZISTA r 53 Fondaparinux 53 Long Term Outcomes 53 peg interferon 53 Aripiprazole 53 FOLFOX4 53 Stent Thrombosis 53 Phase Ib clinical 53 Osteoporosis Treatment 53 Investigational Treatment 53 double blinded placebo 53 Stenting 53 Drug Eluting Stents 53 Induces 53 placebo controlled Phase III 53 pharmacokinetic parameters 53 Phase III randomized 53 blinded randomized placebo controlled 53 IND Application 53 evaluating tivozanib 53 relapsing multiple sclerosis 53 #μg [002] 53 RoACTEMRA 53 Targeted Therapy 53 guanfacine extended release 53 pharmacodynamic effects 53 Tesamorelin 53 Acute Coronary Syndromes 53 Novel Mechanism 53 Tanespimycin 53 Amrubicin 53 Prophylactic 53 Diabetic Foot Ulcer 53 Quadrivalent 53 plus methotrexate 53 Lamotrigine 53 Multicenter Trial 53 FOLFIRI 53 TMC# [001] 53 DAPT 53 sorafenib Nexavar 53 dosage regimens 53 SVR# 53 Significant Efficacy 53 CAMMS# 53 somatostatin analog 53 davunetide intranasal AL 53 monotherapy 52 Randomized Phase III 52 Androgen Deprivation Therapy 52 mapatumumab 52 tipranavir 52 HMG CoA reductase inhibitors 52 Psoriasis Area 52 Ischemic 52 Hepatitis C Patients 52 Lenalidomide 52 See CLINICAL PHARMACOLOGY 52 Cardiotoxicity 52 PRECISE 52 Quetiapine 52 Score IPSS 52 aripiprazole 52 Hepatitis C Genotype 52 Replacement Therapy 52 Carboplatin Paclitaxel 52 Spectrum Pharmaceuticals Announces 52 TAXUS Stent 52 Progenitor Cells 52 Fluticasone 52 PEGylated Fab fragment 52 Based Regimens 52 Initiate Phase III 52 safety tolerability pharmacokinetic 52 Lipid Lowering 52 Coronary Stent 52 rilonacept 52 Certolizumab 52 Clostridium difficile Infection 52 Observational Study 52 Immunogenic 52 Skeletal Muscle 52 Exacerbation 52 Menstrual Pain 52 SUSTENNA TM 52 Dabigatran etexilate 52 antiviral activity 52 prospective observational 52 Multimeric 52 Complicated Skin 52 Kidney Transplant Recipients 52 Dasatinib 52 LEVAQUIN ® 52 Immunomodulatory 52 HER2 Positive Breast Cancer 52 5-FU/LV 52 Present Preclinical Data 52 Unstable Angina 52 STRIDE PD 52 Diabetic Neuropathy 52 FOLFOX6 52 secondary efficacy endpoints 52 Engerix B 52 Fidaxomicin 52 Olanzapine 52 multicenter 52 Topical Gel 52 tolerated dose MTD 52 mcg kg 52 CORD II 52 VAPRISOL 52 Oral Mucositis 52 tolterodine ER 52 Adjunctive 52 Aggressive Drug Evaluation 52 decitabine 52 ST Segment Elevation 52 Abatacept 52 Oral Anticoagulant 52 PKC# 52 Juvenile Idiopathic Arthritis 52 Antiangiogenic 52 Catheter Ablation 52 Ozarelix 52 CYPHER ® Sirolimus eluting 52 Pain Intensity 52 interferon alfa 2b 52 Recombinant Human 52 favorable pharmacokinetic profile 52 Ambrisentan 52 Diabetic Nephropathy 52 Blind Placebo Controlled 52 NOXAFIL Oral Suspension 52 lumbar spine bone 52 APTIVUS r 52 Capesaris 52 Potency 52 Endovascular Treatment 52 FUSILEV enhances 52 idraparinux 52 Laquinimod 52 R adalimumab 52 Humanized Anti 52 Intranasal 52 HCV Protease Inhibitor 52 etanercept 52 Fludarabine 52 Taxotere R 52 Radiofrequency Ablation RFA 52 Abstract # 52 certolizumab pegol 52 placebo controlled Phase 52 erlotinib Tarceva ® 52 protease inhibitor PI 52 primary hypercholesterolemia 52 Cardiac Resynchronization 52 randomized blinded 52 oral renin inhibitor 52 Initiates Phase II 52 Interferon Alpha 52 Potent Inhibitor 52 MADIT II 52 antiretroviral naive 52 QTc 52 hemagglutination inhibition HAI 52 CIMZIA TM certolizumab pegol 52 Darunavir 52 Dalbavancin 52 Pharmacokinetic Pharmacodynamic 52 Chronic Hepatitis B 52 Interferon Gamma 52 paclitaxel poliglumex 52 LIALDA 52 Pharmacokinetic parameters 52 Omacetaxine 52 FREEDOMS 52 Invasive Fungal Infections 52 Azacitidine 52 Proves Effective 52 ARCOXIA 52 hemostatic efficacy 52 tolvaptan 52 FDA Approvals 52 FEMALES SHOULD BE ADVISED 52 Bone Metastases 52 efficacy endpoints 52 Ambulatory Blood Pressure 52 Virologic Response 52 Clinical Trial Data 52 Intravesical 52 Secondary Hyperparathyroidism 52 ceftazidime 52 weekly subcutaneous injections 52 Valopicitabine NM# 52 Hepatotoxicity 52 Mg Uk 52 plus ribavirin 52 Neoadjuvant Chemotherapy 52 Combination REOLYSIN R 52 Receptor Antagonist 52 Renal Impairment 52 Phase IIA 52 Telithromycin 52 Genotypes 52 hematological parameters 52 Dexamethasone 52 BARACLUDE R 52 Ezetimibe 52 BARACLUDE r 52 Secondary endpoints include 52 SPIRIVA ® 52 Chronic Heart Failure 52 Degarelix 52 Complete Remission 52 Ranibizumab 52 Symptom Improvement 52 tapentadol ER 52 NPH insulin 52 Lipid Lowering Treatment 52 Liposomal 52 Phase 2a Study 52 Balloon Angioplasty 52 multicenter Phase III 52 transdermal estradiol 52 Interferon alfa 52 Adverse Event 52 Myelodysplastic Syndrome MDS 52 Metastatic Pancreatic Cancer 52 Percutaneous 52 abacavir Ziagen 52 BOLDER II 52 Induction Chemotherapy 52 Pafuramidine 52 Atomoxetine 52 BEACOPP 52 fluvoxamine 52 Tigecycline 52 Fracture Risk 52 PRN FDA Approves 52 Anticoagulation 52 atazanavir ritonavir 52 pegylated interferon alfa 2a 52 Endeavor Drug Eluting 52 Shows Promising 52 Oral Insulin 52 Alendronate 52 noninferior 52 multicentre randomized double 52 azilsartan medoxomil 52 Improve Survival 52 Neuroprotective Effects 52 randomized trials 52 pimecrolimus cream 52 lopinavir ritonavir 52 SPIRIT III 52 ULORIC 52 briakinumab 52 fluticasone furoate 52 EGFR HER2 52 Main Outcome Measures 52 Lubiprostone 52 prespecified 52 Phase 1b 52 Chronic Renal Failure 52 eluting stent 52 Kinase Inhibitor 52 PEGylated anti 52 LCP Tacro 52 Allogeneic 52 anti leukemic 52 Phase 1b trial 52 Interferon Alfa 52 Irinotecan 52 Fluorouracil 52 sotalol 52 Antiretroviral Therapy 52 RE LY trial 52 Randomised Trial 52 #mg/m# [002] 52 Bronchodilator 52 RAPAFLO R 52 Corticosteroid 52 multicenter Phase 52 sirolimus eluting 52 Hormone Receptor Positive 52 FDA Approves 52 Atopic Dermatitis 52 pharmacokinetic 52 Darusentan 52 pharmacokinetic profiles 52 Initiate Clinical Trial 52 Prognostic Significance 51 ROZEREM TM 51 Outpatient Setting 51 Eluting Coronary Stent System 51 Microplasmin 51 HORIZONS AMI 51 HCV RESPOND 2 51 Gout Drug 51 Receptor Agonist 51 virological response 51 alfuzosin 51 sirolimus eluting stents 51 dose atorvastatin 51 Brain Metastases 51 Trastuzumab 51 rFVIIa 51 Patients Suffering 51 Data Suggest 51 Biphasic 51 Dendritic Cells 51 Isavuconazole 51 azacitidine 51 Phase IIIb clinical 51 Phase III Clinical Trials 51 Receives Orphan Drug Designation 51 Epratuzumab 51 retinal thickness 51 Etanercept 51 lispro 51 mm Stent 51 Glufosfamide 51 postmenopausal osteoporotic women 51 Raloxifene Evaluation MORE 51 Interferon alpha 2b 51 statistically significant improvement 51 cyclophosphamide doxorubicin vincristine 51 QLT# 51 pharmacokinetic profile 51 Angiographic 51 Methotrexate 51 PROVENGE ® 51 Preclinical Efficacy 51 Ischemic Stroke 51 ORMD 51 Recurrent Breast Cancer 51 Comorbidities 51 clomipramine 51 Xelox 51 Prognostic Value 51 Interferon beta 1b 51 adefovir dipivoxil 51 q#h 51 Carfilzomib 51 Pharmacological 51 Inflammatory Pain 51 alfa 2b 51 Remission Maintenance

Back to home page